Yet, the only immune characteristic found to predict a poor clinical outcome in MM was the PD-1 checkpoint expressed on PB CD4 Teff cells; patients with higher expression of PD-1 had an unfavorable clinical course and tended to live shorter. This evidence concerns the gene CD4 and Miyoshi myopathy.